

Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) **EP 1 288 224 A1**

(12) **EUROPEAN PATENT APPLICATION**

(43) Date of publication:
05.03.2003 Bulletin 2003/10

(51) Int Cl.7: **C07K 7/08, C07K 14/655**

(21) Application number: **02026863.7**

(22) Date of filing: **08.08.1994**

(84) Designated Contracting States:
**AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL
PT SE**
Designated Extension States:
LT SI

(72) Inventor: **The designation of the inventor has not yet been filed**

(74) Representative: **Owen, Deborah Jane)
Frank B. Dehn & Co.
179 Queen Victoria Street
London EC4V 4EL (GB)**

(30) Priority: **09.08.1993 US 104194**

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
94924590.6 / 0 788 509

Remarks:

This application was filed on 02 - 12 - 2002 as a
divisional application to the application mentioned
under INID code 62.

(71) Applicant: **Biomeasure Incorporated
Milford, MA 01757-3650 (US)**

(54) **Therapeutic peptide derivatives**

(57) Peptide derivatives containing one or more
substituents separately linked by an amide, amino or
sulfonamide bond to an amino group on either the N-

terminal end or side chain of a biologically active peptide
moiety. The peptide derivatives have relatively en-
hanced biological activity when compared to the corre-
sponding peptide alone.




Fig. 1

Description

Background of the Invention

[0001] This invention relates to therapeutic peptides.


[0002] Several attempts have been made to prolong the activity of biologically active peptides. For example, peptides have been chemically modified by synthetically adding sugar moieties to increase the period during which the peptide is active (Sandoz, WO 88/02756; Sandoz, WO 89/09786; DE 3910667 A1, EPO 0 374 089 A2 (1990); and Breipohl, U.S. Patent No. 4,861,755 (1989)). The addition of cationic anchors (EPO 0 363 589 A2 (1990)) and lipid moieties (Whittaker, WO 91/09837; Jung, U.S. Patent No. 4,837,303 (1989)) has also been used to increase the lifetime of the peptide.

Summary of the Invention

[0003] In general, the present invention provides derivatives of biologically active peptides which contain one or more substituents separately bonded to an amino group located on the N-terminal end or a side chain of the peptide moiety. In this modified form, the derivatives have more potent and prolonged biological activity than the corresponding unmodified peptide.

[0004] The peptide derivatives are advantageous in that they are inexpensive, highly biocompatible, lack deleterious side effects, and are compatible with different forms of therapeutic administration. In particular, many of the derivatives which have somatostatin as the peptide moiety have improved greatly improved potency and selectivity compared to unmodified somatostatin.

[0005] In one aspect, the invention features a peptide derivative containing a biologically active peptide moiety and at least one substituent attached to the peptide moiety; the substituent is selected from the group including Compounds I, II, and III, where Compound I is:



where:


R_0 is O, S, or NR_5 , where R_5 is H or (C_1-C_6) alkyl; each R_1 and R_2 , independently, is H, $(CH_2)_mOR_6$, or $CH(OR_7)CH_2OR_8$, where R_6 is H or (C_2-C_7) acyl, and each R_7 and R_8 , independently, is H, (C_2-C_7) acyl, or $C(R_9)(R_{10})$, where each R_9 and R_{10} , independently, is H or (C_1-C_6) alkyl;

or each R_1 and R_2 is $=CHCH_2OR_{11}$, wherein in R_{11} ,

each R_1 and R_2 , independently, is H or (C_2-C_7) acyl, and m is an integer between 1 and 5, inclusive; and

one of R_3 or R_4 is $(CH_2)_nR_{12}$ or $(CH_2)_nCH(OH)R_{12}$, where R_{12} is CO, CH_2 , or SO_2 , and n is an integer between 1 and 5, inclusive; and the remaining R_3 or R_4 is H, (C_1-C_6) hydroxyalkyl, or (C_2-C_7) acyl; and

Compound II is:




where:

each R_{13} , R_{14} and R_{15} , independently, is H or (C_2-C_{24}) acyl;

R_{16} is NH or absent;
 R_{17} is CO, O, or absent;
 R_{18} is CO, CH_2 , SO_2 , or absent; and
 m is an integer between 1 and 5, inclusive; and n
 is an integer between 0 and 5, inclusive; and

Compound III is:



where:

R_{19} is H, NH_2 , an aromatic functional group, OH, $(\text{C}_1\text{--C}_6)$ hydroxyalkyl, $\text{H}(\text{R}_{27})(\text{R}_{28})$, SO_3H , or absent where each
 R_{27} and R_{28} , independently, is H or $(\text{C}_1\text{--C}_6)$ alkyl;
 R_{20} is O or absent;
 R_{21} is $(\text{C}_1\text{--C}_6)$ alkyl or absent;
 R_{22} is N, CH, O, or C;
 $\text{---R}_{23}\text{---}$ is $(\text{C}_1\text{--C}_6)$ alkyl or absent;
 R_{24} is N, CH, or C;
 R_{25} is NH, O, or absent;
 R_{26} is SO_2 , CO, CH_2 , or absent;
 m is an integer between 0 and 5, inclusive;
 n is an integer between 0 and 5, inclusive;
 p is an integer between 0 and 5, inclusive; and
 q is an integer between 0 and 5, inclusive.

[0006] In Compounds I, II and III the peptide moiety is attached to each of the substituents by a CO-N, $\text{CH}_2\text{---N}$, or $\text{SO}_2\text{---N}$ bond between the substituent and a nitrogen atom of the N-terminus or a side chain of said peptide moiety.

[0007] In preferred embodiments, $\text{---R}_{23}\text{---}$ is $(\text{C}_1\text{--C}_6)$ alkyl; R_{22} is N, C or CH; and R_{24} is C. Alternatively, R_{22} is O; R_{19} , R_{20} , R_{21} , and $\text{---R}_{23}\text{---}$ are absent; and the sum of m and n is 3, 4, or 5.


[0008] In other preferred embodiments of the invention, the substituent is Compound I; in this embodiment, R_{12} is preferably CH_2 or SO_2 . Alternatively, the substituent may be Compound II, in which case R_{18} is preferably CH_2 or SO_2 ; R_{13} , R_{14} , and R_{15} are H; and R_{17} is absent. In particularly preferred embodiments, the substituent is $(\text{HOCH}_2)_3\text{C}\text{---NH}\text{---}(\text{CH}_2)_2\text{---SO}_2$ or $(\text{HOCH}_2)_3\text{C}\text{---CH}_2\text{---}$.

[0009] In still other embodiments of the invention, the substituent is Compound III; preferably, in this embodiment, $\text{---R}_{23}\text{---}$ is absent and at least one of R_{22} and R_{24} is N. Alternatively, both R_{22} and R_{24} may be N.

[0010] In other embodiments, the substituent is one of:




and




[0011] Preferably, the peptide moiety is selected from the group including: somatostatin, bombesin, calcitonin, calcitonin gene related peptide (CGRP), amylin, parathyroid hormone (PTH), gastrin releasing peptide (GRP), melanocyte stimulating hormone (MSH), adrenocorticotrophic hormone (ACTH), parathyroid related peptide (PTHrP), luteinizing hormone-releasing hormone (LHRH), growth hormone releasing factor (GHRF), growth hormone releasing peptide (GHRP), cholecystokinin (CCK), glucagon, Bradykinin, glucagon-like peptide (GLP), gastrin, enkephalin, neuromedins, endothelin, substance P, neuropeptide Y (NPY), peptide YY (PYY), vasoactive intestinal peptide (VIP), guanylin, pituitary adenylate cyclase activating polypeptide (PACAP), beta-cell tropin, adrenomedulin, and derivatives, fragments, and analogs thereof.

[0012] The peptide moiety is preferably somatostatin or a derivative, fragment, or analog thereof. Most preferably, the somatostatin analog is one of: H-D-Phe-c[Cys-Tyr-D-Trp-Lys-Abu-Cys]-Thr-NH₂, H-D-Phe-c[Cys-Tyr-D-Trp-Lys-Thr-Cys]-Nal-NH₂, and H-D-Nal-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Thr-NH₂. Alternatively, the peptide moiety is bombesin or a derivative, fragment or analog thereof.

[0013] In still other preferred embodiments, the peptide derivative is one of:



and



[0014] In another aspect, the invention provides a dimeric peptide derivative containing two biologically active peptide moieties, and at least one substituent attached to each of the peptide moieties. The substituent is selected from the group consisting of compounds IV and V, where compound IV has a generic structure equivalent to compound I, and compound V has a generic structure equivalent to compound III. In the dimer, each of the peptide moieties is attached to the substituents by a CO-N, CH₂-N, or SO₂-M bond between the substituent and a nitrogen atom of the N-terminus or a side chain of one of the peptide moieties.

[0015] In yet another aspect, the invention provides a method for treating a disease, such as cancer, in a patient; the method includes the step of administering to the patient a therapeutic amount of the peptide derivatives described herein. In preferred embodiments, the peptide moiety used in the treatment is somatostatin.

[0016] By "biologically active", as used herein, is meant a naturally occurring, recombinant, and synthetic peptide having physiological or therapeutic activity. In general, this term covers all derivatives, fragments, and analogs of biologically active peptides which exhibit a qualitatively similar or opposite effect to that of the unmodified peptide.

Brief Description of the Drawings

[0017]

Fig. 1 is a graph of two growth curves of AR42J cells in the presence of different somatostatin derivatives.

Description of the Preferred Embodiments





Peptide Derivatives

[0018] In general, peptide derivatives of the invention contain two separate components: 1) a biologically active

peptide; and, 2) at least one substituent having the structure of Compounds I, II, and III. Peptide derivatives made according to the methods described herein include the following compounds.

Compound I-Based Derivatives


[0019]



wherein $\text{R}_0, \text{R}_1, \text{R}_2, \text{R}_3, \text{R}_4, \text{R}_{12}$, and n are as defined herein, and $\text{NH-P}'$ is the biologically active peptide moiety. In these embodiments, the NH group is located on the N-terminal end or side chain of the peptide and P' represents the remainder of the peptide.

Compound II-based Derivatives

[0020]



wherein $\text{R}_{13}, \text{R}_{14}, \text{R}_{15}, \text{R}_{16}, \text{R}_{17}, \text{R}_{18}, m, n$, and $\text{NH-P}'$ are as defined herein.

$$\begin{array}{c} \text{(CH}_2\text{)}_m \\ \diagup \quad \diagdown \\ \text{R}_{19}-\text{R}_{20}-\text{R}_{21}-\text{R}_{22} - \text{R}_{23} - \text{R}_{24}-\text{R}_{25}-(\text{CH}_2)_p-\text{R}_{26}-\text{NH}-\text{P}' \\ \diagdown \quad \diagup \\ \text{(CH}_2\text{)}_n \end{array}$$

[0025] In especially preferred embodiments, the peptide moiety is somatostatin or a derivative, fragment, or analog of somatostatin. Somatostatin analogs which can be used in accordance with the present invention include, but are not limited to the following compounds:

H-Phe-Pen-Phe-D-Trp-Lys-Thr-Pen-Thr;

H-D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-ol;
 H-D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH₂;
 5 H-D-Trp-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH₂;
 H-D-Trp-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH₂;
 H-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH₂;
 10 H-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Trp-NH₂;
 H-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH₂;
 Ac-D-Phe-Lys^{*}-Tyr-D-Trp-Lys-Val-Asp-Thr-NH₂
 Ac-hArg(Et)₂-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-
 15 Thr-NH₂;
 Ac-D-hArg(Et)₂-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-
 NH₂;
 20 Ac-D-hArg(Bu)-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-
 NH₂;
 Ac-D-hArg(Et)₂-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH₂;
 25 Ac-L-hArg(Et)₂-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH₂;
 Ac-D-hArg(CH₂CF₃)₂-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-
 NH₂;
 30 Ac-D-hArg(CH₂CF₃)₂-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-
 Thr-NH₂;
 Ac-D-hArg(CH₂CF₃)₂-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-
 Phe-NH₂;
 35 Ac-D-hArg(CH₂CF₃)₂-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-
 Thr-NH₂;
 Ac-L-hArg(CH₂-CF₃)₂-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-
 40 Thr-NH₂;
 Ac-D-hArg(CH₂CF₃)₂-Gly-Cys-Phe-D-Trp-Lys(Me)-Thr-
 Cys-Thr-NH₂;
 45 Ac-D-hArg(CH₂CF₃)₂-Gly-Cys-Phe-D-Trp-Lys(Me)-Thr-
 Cys-Thr-NH₂;
 Ac-hArg(CH₃, hexyl)-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-
 Thr-NH₂;
 50 H-hArg(hexyl)₂-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-
 NH₂;
 55

Ac-D-hArg(Et)₂-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-
 NH₂;
 5 Ac-D-hArg(Et)₂-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Phe-
 NH₂;
 Propionyl-D-hArg(Et)₂-Gly-Cys-Phe-D-Trp-Lys(iPr)-
 10 Thr-Cys-Thr-NH₂;
 Ac-D-β-Nal-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Gly-
 hArg(Et)₂-NH₂;
 15 Ac-D-Lys(iPr)-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-
 NH₂;
 Ac-D-hArg(CH₂CF₃)₂-D-hArg(CH₂CF₃)₂-Gly-Cys-Phe-D-
 20 Trp-
 Lys-Thr-Cys-Thr-NH₂;
 Ac-D-hArg(CH₂CF₃)₂-D-hArg(CH₂CF₃)₂-Gly-Cys-Phe-
 D-Trp-Lys-Thr-Cys-Phe-NH₂;
 25 Ac-D-hArg(Et)₂-D-hArg(Et)₂-Gly-Cys-Phe-D-Trp-Lys-
 Thr-Cys-Thr-NH₂;
 Ac-Cys-Lys-Asn-4-Cl-Phe-Phe-D-Trp-Lys-Thr-Phe-
 30 Thr-Ser-D-Cys-NH₂;
 Bmp-Tyr-D-Trp-Lys-Val-Cys-Thr-NH₂;
 Bmp-Tyr-D-Trp-Lys-Val-Cys-Phe-NH₂;
 35 Bmp-Tyr-D-Trp-Lys-Val-Cys-p-Cl-Phe-NH₂;
 Bmp-Tyr-D-Trp-Lys-Val-Cys-β-Nal-NH₂;
 H-D-β-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH₂;
 H-D-Phe-Cys-Tyr-D-Trp-Lys-Abu-Cys-Thr-NH₂;
 40 H-D-Phe-Cys-Tyr-D-Trp-Lys-Abu-Cys-β-Nal-NH₂;
 H-pentafluoro-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-
 NH₂;
 45 Ac-D-β-Nal-Cys-pentafluoro-Phe-D-Trp-Lys-Val-Cys-
 Thr-NH₂;
 H-D-β-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-β-Nal-NH₂;
 H-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-β-Nal-NH₂;
 50 H-D-β-Nal-Cys-Tyr-D-Trp-Lys-Abu-Cys-Thr-NH₂;
 H-D-p-Cl-Phe-Cys-Tyr-D-Trp-Lys-Abu-Cys-Thr-NH₂;
 Ac-D-p-Cl-Phe-Cys-Tyr-D-Trp-Lys-Abu-Cys-Thr-NH₂;
 55

H-D-Phe-Cys- β -Nal-D-Trp-Lys-Val-Cys-Thr-NH₂;
 H-D-Phe-Cys-Tyr-D-Trp-Lys-Cys-Thr-NH₂;
 5 cyclo (Pro-Phe-D-Trp-N-Me-Lys-Thr-Phe) ;
 cyclo (Pro-Phe-D-Trp-N-Me-Lys-Thr-Phe) ;
 cyclo (Pro-Phe-D-Trp-Lys-Thr-N-Me-Phe) ;
 cyclo (N-Me-Ala-Tyr-D-Trp-Lys-Thr-Phe) ;
 10 cyclo (Pro-Tyr-D-Trp-Lys-Thr-Phe) ;
 cyclo (Pro-Phe-D-Trp-Lys-Thr-Phe) ;
 cyclo (Pro-Phe-L-Trp-Lys-Thr-Phe) ;
 15 cyclo (Pro-Phe-D-Trp(F)-Lys-Thr-Phe) ;
 cyclo (Pro-Phe-Trp(F)-Lys-Thr-Phe) ;
 cyclo (Pro-Phe-D-Trp-Lys-Ser-Phe) ;
 20 cyclo (Pro-Phe-D-Trp-Lys-Thr-p-Cl-Phe) ;
 cyclo (D-Ala-N-Me-D-Phe-D-Thr-D-Lys-Trp-D-Phe) ;
 cyclo (D-Ala-N-Me-D-Phe-D-Val-Lys-D-Trp-D-Phe) ;
 25 cyclo (D-Ala-N-Me-D-Phe-D-Thr-Lys-D-Trp-D-Phe) ;
 cyclo (D-Abu-N-Me-D-Phe-D-Val-Lys-D-Trp-D-Tyr) ;
 cyclo (N-Me-Ala-Tyr-D-Trp-Lys-Val-Phe) ;
 cyclo (Pro-Tyr-D-Trp-4-Amphe-Thr-Phe) ;
 30 cyclo (Pro-Phe-D-Trp-4-Amphe-Thr-Phe) ;
 cyclo (N-Me-Ala-Tyr-D-Trp-4-Amphe-Thr-Phe) ;
 cyclo (Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Gaba) ;
 35 cyclo (Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Gaba-Gaba) ;
 cyclo (Asn-Phe-D-Trp-Lys-Thr-Phe) ;
 cyclo (Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-NH(CH₂)₄CO) ;
 40 cyclo (Asn-Phe-Phe-D-Trp-Lys-Thr-Phe- β -Ala) ;
 cyclo (Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-D-Glu)-OH ;
 cyclo (Phe-Phe-D-Trp-Lys-Thr-Phe) ;
 cyclo (Phe-Phe-D-Trp-Lys-Thr-Phe-Gly) ;
 45 cyclo (Phe-Phe-D-Trp-Lys-Thr-Phe-Gaba) ;
 cyclo (Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Gly) ;
 cyclo (Asn-Phe-Phe-D-Trp(F)-Lys-Thr-Phe-Gaba) ;
 50 cyclo (Asn-Phe-Phe-D-Trp(NO₂)-Lys-Thr-Phe-Gaba) ;
 cyclo (Asn-Phe-Phe-Trp(Br)-Lys-Thr-Phe-Gaba) ;
 cyclo (Asn-Phe-Phe-D-Trp-Lys-Thr-Phe(I)-Gaba) ;
 55

cyclo (Asn-Phe-Phe-D-Trp-Lys-Thr-Tyr(But)-Gaba) ;
 cyclo (Bmp-Lys-Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr-
 5 Pro-Cys)-OH;
 cyclo (Bmp-Lys-Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr-
 Pro-Cys)-OH;
 10 cyclo (Bmp-Lys-Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr-
 Tpo-Cys)-OH;
 cyclo (Bmp-Lys-Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr-
 MeLeu-Cys)-OH;
 15 cyclo (Phe-Phe-D-Trp-Lys-Thr-Phe-Phe-Gaba) ;
 cyclo (Phe-Phe-D-Trp-Lys-Thr-Phe-D-Phe-Gaba) ;
 cyclo (Phe-Phe-D-Trp(5F)-Lys-Thr-Phe-Phe-Gaba) ;
 20 cyclo (Asn-Phe-Phe-D-Trp-Lys(Ac)-Thr-Phe-NH-
 (CH₂)₃-CO) ;
 cyclo (Lys-Phe-Phe-D-Trp-Lys-Thr-Phe-Gaba) ;
 25 cyclo (Lys-Phe-Phe-D-Trp-Lys-Thr-Phe-Gaba) ; and
 cyclo (Orn-Phe-Phe-D-Trp-Lys-Thr-Phe-Gaba)


where Lys* indicates an amide bridge formed between Lys* and Asp.

[0026] The peptide compounds listed above are described in the following references, each of which is incorporated herein by reference:

[0027] EP Application No. P5 164 EU; Van Binst, G. et al. Peptide Research 5:8 (1992); Horvath, A. et al. Abstract, "Conformations of Somatostatin Analogs Having Anti-tumor Activity", 22nd European Peptide Symposium, September 13-19, 1992, Interlaken, Switzerland; PCT Application WO 91/09056 (1991); EP Application 0 363 589 A2 (1990); EP Application 0 203 031 A2 (1986); U.S. Patent Nos. 4,904,642; 4,871,717; 4,853,371; 4,725,577; 4,684,620; 4,650,787; 4,603,120; 4,585,755; 4,522,813; 4,486,415; 4,485,101; 4,435,385; 4,395,403; 4,369,179; 4,360,516; 4,358,439; 4,328,214; 4,316,890; 4,310,518; 4,291,022; 4,238,481; 4,235,886; 4,224,190; 4,211,693; 4,190,648; 4,146,612; and 4,133,782.

[0028] In the somatostatin analogs listed above, each amino acid residue has the structure of NH-C(R)H-CO-, in which R is the side chain; lines between amino acid residues represent peptide bonds which join the amino acids. When the amino acid residue is optically active, it is the L-form configuration that is intended unless the D-form is expressly designated. When two Cys residues are present in the peptide, a disulfide bridge is formed between the two moieties. This bond, however, is not shown in the listed residues.

[0029] Additionally preferred somatostatin analogs of the invention are of the following formula:



wherein A₁ is a D- or L-isomer of β-Nal, Trp, β-pyridyl-Ala, Phe, substituted Phe, or deleted; and each A₂ and A₇, independently, is Cys, Asp, or Lys. These moieties are covalently linked to each other via a disulfide bridge or an amide bridge. In addition, A₃ is β-Nal, Phe, or o-, m-, or p-substituted X-Phe where X is a halogen, OH, NH₂, NO₂ or C₁₋₃

alkyl; A₆ is Val, Thr, Ser, Ala, Phe, β-Nal, Abu, Ile, Nle, or Nva; and A₈ is Phe, Thr, Tyr, Trp, Ser, β-Nal, an alcohol group, or deleted; each R₁ and R₂, independently, is H, lower acyl or lower alkyl; and R₃ is OH, NH₂, or deleted. Preferably, when one of A₂ and A₇ is Cys, the other is also Cys; when A₈ is an alpha-amino alcohol, R₃ is deleted; and when neither of A₂ and A₇ is Cys, A₂ is different from A₇.

[0030] Especially preferred somatostatin analogs of this embodiment are:

Me-D-Phe-Cys-Tyr-Tyr-D-Trp-Lys-Val-Cys-Thr-NH₂;

H-D-Nal-Cys-Tyr-D-Trp-Lys-Thr-Cys-Nal-NH₂;


H-D-Nal-Cys-Tyr-D-Trp-Lys-Thr-Cys-Thr-NH₂;

H-D-Phe-Cys-Tyr-D-Trp-Lys-Abu-Cys-Thr-NH₂;

H-D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Cys-Nal-NH₂; and

H-D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Cys-Thr-ol.

[0031] In other embodiments, linear somatostatin analogs of the invention have the following structure:



wherein A¹ is a D- or L- isomer of Ala, Leu, Ile, Val, Nle, Thr, Ser, β-Nal, β-pyridyl-Ala, Trp, Phe, 2,4-dichloro-Phe, pentafluoro-Phe, p-X-Phe, or o-X-Phe, wherein X is CH₃, Cl, Br, F, OH, OCH₃ or NO₂;

A² is Ala, Leu, Ile, Val, Nle, Phe, β-Nal, pyridyl-Ala, Trp, 2,4-dichloro-Phe, pentafluoro-Phe, o-X-Phe, or p-X-Phe, wherein X is CH₃, Cl, Br, F, OH, OCH₃ or NO₂;

A³ is pyridyl-Ala, Trp, Phe, β-Nal, 2,4-dichloro-Phe, pentafluoro-Phe, o-X-Phe, or p-X-Phe, wherein X is CH₃, Cl, Br, F, OH, OCH₃ or NO₂;

A⁶ is Val, Ala, Leu, Ile, Nle, Thr, Abu, or Ser;

A⁷ is Ala, Leu, Ile, Val, Nle, Phe, β-Nal, pyridyl-Ala, Trp, 2,4-dichloro-Phe, pentafluoro-Phe, o-X-Phe, or p-X-Phe, wherein X is CH₃, Cl, Br, F, OH, OCH₃ or NO₂;

A⁸ is a D- or L-isomer of Ala, Leu, Ile, Val, Nle, Thr, Ser, Phe, β-Nal, pyridyl-Ala, Trp, 2,4-dichloro-Phe, pentafluoro-Phe, p-X-Phe, or o-X-Phe, wherein X is CH₃, Cl, Br, F, OH, OCH₃ or NO₂, or an alcohol thereof; and

each R₁ and R₂, independently, is H, lower acyl or lower alkyl; and R₃ is OH, NH₂, or deleted. Preferably, at least one of A¹ and A⁸ and one of A² and A⁷ must be an aromatic amino acid; and when A⁸ is an alcohol, R₃ is deleted. Additionally, A¹, A², A⁷ and A⁸ cannot all be aromatic amino acids. Particularly preferred analogs of this aspect of the invention include:

H-D-Phe-p-chloro-Phe-Tyr-D-Trp-Lys-Thr-Phe-Thr-NH₂;

H-D-Phe-p-NO₂-Phe-Tyr-D-Trp-Lys-Val-Phe-Thr-NH₂;

H-D-Nal-p-chloro-Phe-Tyr-D-Trp-Lys-Val-Phe-Thr-NH₂;

H-D-Phe-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr-NH₂;

H-D-Phe-Phe-Tyr-D-Trp-Lys-Val-Phe-Thr-NH₂;

H-D-Phe-p-chloro-Phe-Tyr-D-Trp-Lys-Val-Phe-Thr-NH₂; and

H-D-Phe-Ala-Tyr-D-Trp-Lys-Val-Ala-D-β-Nal-NH₂.

[0032] In still other preferred embodiments, the peptide moiety is bombesin or a derivative, fragment, or analog of bombesin. Bombesin analogs which can be used to practice the present invention include, but are not limited to, Neuromedin C, Neuromedin B, litorin, and gastrin-releasing peptide (GRP), which has the following amino acid sequence:

H-Ala-Pro-Val-Ser-Val-Gly-Gly-Gly-Thr-Val-Leu-Ala-Lys-Met-Tyr-Pro-Arg-Gly-Asn-His-Trp-Ala-Val-Gly-His-Leu-Met-NH₂

[0033] Other bombesin analogs which may be used in the present invention include compounds described in the following references, the contents of which are incorporated herein by reference:

[0034] Coy et al. Peptides, Proceedings of the Eleventh Amer. Peptide Symposium, Ed. by Rivier et al. ESCOM, pp. 65-67 (1990); Wang et al. J. Biol. Chem. 265:15695 (1990); Mahmoud et al. Cancer Research 51:1798 (1991); Wang et al. Biochemistry 29:616 (1990); Heimbrook et al., "Synthetic Peptides: Approaches to Biological Problems", UCLA Symposium on Mol. and Cell. Biol. New Series, Vol. 86, ed. Tam and Kaiser; Martinez et al., J. Med. Chem. 28:1874 (1985); Gargosky et al., Biochem. J. 247:427 (1987); Dubreuil et al., Drug Design and Delivery, Vol 2:49, Harwood Academic Publishers, GB (1987); Heikkila et al., J. Biol. Chem. 262:16456 (1987); Caranikas et al., J. Med. Chem. 25:1313 (1982); Saeed et al., Peptides 10:597 (1989); Rosell et al., Trends in Pharmacological Sciences 3:211 (1982); Lundberg et al., Proc. Nat. Aca. Sci. 80:1120, (1983); Engberg et al., Nature 293:222 (1984); Mizrahi et al., Euro. J. Pharma. 82:101 (1982); Leander et al., Nature 294:467 (1981); Woll et al., Biochem. Biophys. Res. Comm. 155:359 (1988); Rivier et al., Biochem. 17:1766 (1978); Cuttitta et al., Cancer Surveys 4:707 (1985); Aumelas et al., Int. J. Peptide Res. 30:596 (1987); Szepeshazi. et al., Cancer Research 51:5980 (1991); Jensen, et al. Trends Pharmacol. Sci. 12:13 (1991); U.S. Patent Nos. 5,028,692; 4,943,561; 4,207,311; 5,068,222; 5,081,107; 5,084,555; EP Application Nos. 0 315 367 A2 (1989); 0 434 979 A1 (1991); 0 468 497 A2 (1992); 0 313 158 A2 (1989); 0 339 193 A1 (1989); PCT Applications Nos. WO 90/01037 (1990); 90/02545 (1992); and UK Application GB 1 231 051 A (1990).

[0035] The peptides of the invention can be provided in the form of pharmaceutically acceptable salts. Examples of preferred salts are those with therapeutically acceptable organic acids, e.g., acetic, lactic, maleic, citric, malic, ascorbic, succinic, benzoic, salicylic, methanesulfonic, toluenesulfonic, or pamoic acid, as well as polymeric acids such as tannic acid or carboxymethyl cellulose, and salts with inorganic acids such as hydrohalic acids, including hydrochloric acid, sulfuric acid, and phosphoric acid.

Synthesis of Compounds

[0036] The syntheses of Compounds I, II and III are now described.

[0037] The following abbreviations are used in describing syntheses of compounds according to the present invention:

Nal: naphthylalanine (1 or 2)

	Abu:	alpha-aminobutyric acid
	D:	dextrorotatory
5	L:	levorotatory
	HOAC:	acetic acid
	BOP:	benzotriazol-1-yloxytris(dimethylamino) phosphonium hexafluoro-phosphate
10	BOC:	tert-butyloxycarbonyl
	DCC:	dicyclohexyl carbodiimide
15	EDC:	1-(3-dimethylaminopropyl)-3-ethylcarbodiimide
	DEPC:	diethylcyanophosphonate
	DMF:	dimethylformamide
20	CH ₂ CL ₂ :	dichloromethane
	MeOH:	methanol
25	EtOH:	ethanol
	DIEA:	N,N-diisopropylethylamine
	HOBT:	1-hydroxybenzotriazole
30	HBTU:	O-Benzotriazol-1-yl,N,N,N',N'-tetramethyluronium hexafluorophosphate
	THF:	Tetrahydrofuran
35	TFA:	Trifluoroacetic Acid

[0038] Starting materials and intermediates for Compounds I, II, and III are commercially available. Alternatively, the starting materials can be easily prepared by methods which are well known and included in the literature. For example, the chemistry of ascorbic acid-related derivatives can be found in *J. Chem. Soc., Perkin Trans. 1*:1220 (1974); *Carbohyd. Res.*, 67:127 (1978); *Yakugaku Zasshi*, 86:376 (1966); U.S. Pat. No. 4,552,888; *J. Med. Chem.*, 31:793 (1988); *ibid.* 34:2152 (1991); and, 35:1618 (1992), the contents of which are incorporated herein by reference. The chemistry for tris-related derivatives can be found in *Arch. Biochem. Biophys.*, 96, 653 (1962), *Biochem.*, 5 467 (1966), the contents of which are also incorporated herein by reference.

45 Synthesis of Peptide Derivatives


[0039] In a general sense, the coupling of Compounds I, II, or III to an appropriate free amino group of a protected amino acid or peptide can be achieved according to well-known methods employed for peptide synthesis (e.g., DCC, DCC-HOBT, DIC-HOBT PPA, EDC-HOBT, DEPT, BOP, HBTU) using a base (e.g., DIEA) in an inert solvent (e.g., DMF, THF or CH₂Cl₂ ethyl acetate or combination thereof). Deblocking of protected groups may also be carried out by well-known methods (e.g., removal of the group by the addition of acid or base, TFA, dioxan-HCl, ammonia, NaOMe, piperidine). In most cases, the reaction temperature should range from -30°C to room temperature.

[0040] In general, the first step of the synthesis involves the reaction between an epoxide and a free amino group of a protected amino acid or peptide; complexation and deprotection can be achieved utilizing well-known methods, such as those described in McManus, et al., *Synth. Communications* 3, 177 (1973), the contents of which are incorporated herein by reference. Following synthesis, purification of the intermediates and products can be achieved by conventional methods such as chromatography or HPLC. The identification of the compounds may be determined by conventional techniques such as NMR, amino acid analysis, and mass spectrometry.

[0041] The following Examples illustrate the preferred methods for forming the compounds of the invention.

Example 1 - Synthesis of Somatostatin Derivatives

[0042] The following somatostatin derivative, also referred to herein as BIM-23118, was synthesized in accordance with the invention:



Example 1.1 - 3-O-(Benzyloxycarbonylmethyl)-2,5,6-triacetyl-ascorbic acid

[0043] Acetic anhydride (6 ml) was added dropwise to a solution of 3-O-(benzyloxycarbonylmethyl)-ascorbic acid (2.2 g) in pyridine (30 ml); the mixture was then stirred overnight at room temperature. Pyridine was evaporated under reduced pressure leaving a residue which was then partitioned between ethyl acetate and 1N HCl. The ethyl acetate layer was washed with 1N HCl, and then water. After drying (MgSO_4), the ethyl acetate was evaporated under reduced pressure; traces of pyridine and acetic anhydride which still remained were removed by multiple co-evaporations with toluene. The resulting 3-O-(Benzyloxycarbonylmethyl)-2,5,6-triacetyl-ascorbic acid was dried under vacuum to yield a viscous gel which remained in the residue (2.4 g). TLC (silica gel: $\text{CHCl}_3/\text{acetone}$ [9:1], $R_f=0.52$).

Example 1.2 - 3-O-(carboxymethyl)-2,5,6-triacetyl-ascorbic acid

[0044] A slurry of Pd-C (100 mg) in water (2 ml) was added to a solution of 3-O-(benzyloxycarbonylmethyl)-2,5,6-triacetyl-ascorbic acid (2.4 g) in ethanol (30 ml), and the suspension was shaken under hydrogen (17 psi) for six hours. The catalyst was then removed by filtration through a celite pad and the filtrate evaporated under reduced pressure to yield 3-O-(carboxymethyl)-2,5,6-triacetyl-ascorbic acid. TLC (silica gel: $\text{CHCl}_3/\text{MeOH}/\text{HOAc}$ [9:1:0.1], $R_f=0.2$).

Example 1.3 - 5,6-O-Isopropylideneascorbic acid

[0045] Acetylchloride (0.67 ml) was added to a rapidly stirred suspension of ascorbic acid (8.0 g) in acetone (80 ml) and the mixture was stirred at room temperature overnight. The precipitate was collected by filtration, washed with ethyl acetate, and dried at reduced pressure to afford 8.29 g of 5,6-O-Isopropylideneascorbic acid as a colorless solid. TLC (silica gel: $\text{CHCl}_3/\text{MeOH}/\text{HOAc}$ [3:1:0.1], $R_f=0.54$).

Example 1.4 - 3-O-(Ethoxycarbonylpropyl)-5,6-isopropylidene-ascorbic acid

[0046] A solution of 5,6-isopropylidene ascorbic acid (2.0 g) in 10 ml DMF was added dropwise to a suspension of NaH (0.44 g of 50% mineral oil NaH dispersion washed with hexane several times) in 5 ml DMF. After gas evolution ceased, a solution of 1.43 ml ethyl 4-bromobutyrate in 5 ml DMF was added dropwise and the mixture was stirred at room temperature overnight. Solvent was evaporated at reduced pressure and the resultant residue was chromatographed on silica gel (55 g) using $\text{CHCl}_3/\text{MeOH}$ (19:1) as an eluant. Appropriate fractions were pooled and solvents removed at reduced pressure to yield a viscous residue containing 3-O-(Ethoxycarbonylpropyl)-5,6-isopropylidene-ascorbic acid (1.1 g).

Example 1.5 - 3-O-(carboxypropyl)-5,6-isopropylidene ascorbic acid

[0047] 4.6 ml of 2N-NaOH was added to a solution of 3-O-(ethoxycarbonylpropyl)-5,6-isopropylidene-ascorbic acid (1.02 g) in 15 ml EtOH. After one hour, most of the ethanol was removed at reduced pressure and the residue was diluted with water (10 ml), and acidified with dil-HCl (pH 3). The solution was then saturated with NaCl and extracted


several times with ethyl acetate; the pooled extracts were then dried using MgSO_4 . Solvent was evaporated at reduced pressure to yield a viscous residue containing 3-O-(carboxypropyl)-5,6-isopropylidene ascorbic acid (0.84 g). TLC: (Silica gel: $\text{CHCl}_3/\text{MeOH}/\text{HOAc}$ [5:1:0.1], $R_f=0.55$).

Example 1.6 - D-Nal-c[Cys-Tyr-D-Trp-Lys(BOC)-Val-Cys]-Thr- NH_2

[0048] A solution of di-tertbutyl dicarbonate (0.36 g) in 10 ml DMF was added dropwise to a solution of D-Nal-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Thr- NH_2 acetate (2 g, BIM-23014) in 45 ml DMF. After two hours at room temperature, solvent was removed under reduced pressure to yield a residue which was then chromatographed on silica gel (150 g) using $\text{CHCl}_3/\text{MeOH}$ (9:1) as an eluant. Appropriate fractions were pooled and solvents removed under reduced pressure to yield a residue containing D-Nal-c[Cys-Tyr-D-Trp-Lys(BOC)-Val-Cys]-Thr- NH_2 (1.45 g). TLC (silica gel: $\text{CHCl}_3/\text{MeOH}$ [3:1], $R_f=0.52$).

Example 1.7 -

[0049]






[0050] 0.2 ml diisopropylethylamine was added to a solution of D-Nal-Cyclo-[Cys-Tyr-D-Trp-Lys(BOC)-Val-Cys]-Thr- NH_2 (300 mg), 3-O-(carboxypropyl)-5,6-isopropylidene ascorbic acid (56 mg) and HBTU (113 mg) in 5 ml DMF. The mixture was then stirred at room temperature overnight, and solvent was removed under reduced pressure. The residue was partitioned between a mixture of ethyl acetate/MeOH and a saturated aqueous NaCl solution, and the ethyl acetate layer was washed with saturated aqueous NaCl, then saturated aqueous NaHCO_3 , and then dried (MgSO_4). Solvent was evaporated under reduced pressure, and the residue was subjected to preparative TLC using a $\text{CHCl}_3/\text{MeOH}$ (8:1) mixture as a developing solvent. The appropriate UV-positive zone was isolated and extracted with $\text{CHCl}_3/\text{MeOH}$. Solvents were removed at reduced pressure to yield the above-identified product (0.20 g). TLC (silica gel: $\text{CHCl}_3/\text{MeOH}$ [5:1], $R_f=0.54$).

Example 1.8 - Removal of BOC Group

[0051] The ascorbic acid derivative containing D-Nal-c[Cys-Tyr-D-Trp-Lys(BOC)-Val-Cys]-Thr- NH_2 (95 mg) shown above was treated with 25% TFA in CHCl_3 for 45 min. at room temperature. Volatile substances were removed under reduced pressure to yield a dried residue which was purified using Vydac C_{18} HPLC and $\text{CH}_3\text{CN}/0.1\%$ aqueous TFA. The final yield was 90 mg (FAB-MS (m/e) 1341).


Example 1.9 - Other Embodiments

[0052] The following somatostatin derivatives were also synthesized in an analogous manner:



Example 2 - Synthesis of BIM-23107

[0053] The following somatostatin derivative, also referred to as BIM-23107, was synthesized in accordance to the invention.



Example 2.1 - (AcO-CH₂)₃-C-NH-CO-(CH₂)₂-CO-D-Nal-c[Cys-Tyr-D-Trp-Lys(BOC)-Val-Cys]-Thr-NH₂


[0054] 0.03 ml DIEA was added to an ice-cooled solution of 2-N-(succinyl)amino-2-(acetoxymethyl)-1,3-propanediol diacetate (83 mg) and HBTU (92 mg) in 2 ml of DMF. After stirring at 0-5° C for 30 minutes, a solution of D-Nal-c[Cys-Tyr-D-Trp-Lys(BOC)-Val-Cys]-Thr-NH₂ (100 mg) in 2 ml DMF, containing 0.03 ml DIEA, was added. The mixture was first stirred at 0-5° C for one hour and then stirred at room temperature overnight. The solvent was removed at reduced pressure to yield a dried residue which was partitioned between ethyl acetate and aqueous saturated NaCl, and the EtOAc layer washed with aqueous 5% NaHCO₃, and finally aqueous saturated NaCl; the resulting solution was then dried using MgSO₄. The solvent was evaporated under reduced pressure leaving a residue containing (AcO-CH₂)₃-C-NH-CO-(CH₂)₂-CO-D-Nal-c[Cys-Tyr-D-Trp-Lys(BOC)-Val-Cys]-Thr-NH₂ (0.14 gm). TLC (Silica Gel: CHCl₃/MeOH/HOAc = 4:1:0.1, R_f=0.82).

Example 2.2 - Removal of BOC group


[0055] 30 mg of the above-identified compound was treated with 50% TFA in CHCl_3 for 45 minutes at room temperature; volatile substances were then removed at reduced pressure to yield a residue. Traces of TFA were co-evaporated with ethanol several times and the residue was titrated with ether and then dried to yield 30 mg of the product (30 mg). TLC (Silica gel: $\text{CHCl}_3/\text{MeOH}/\text{HOAc} = 3:1:1$, $R_f=0.24$).

Example 2.3 - Other Embodiments


[0056] The following somatostatin derivatives were also synthesized in an analogous manner.




BIM-23158




BIM-23167



BIM-23173



BIM-23179



BIM-23182

Example 3 - Synthesis of BIM-23201

[0057] The following somatostatin derivative, also referred to as (BIM-23201), was synthesized in accordance with the present invention.




Example 3.1 - (HO-CH₂)₃-C-CH₂-D-Phe-c[Cys-Tyr-D-Trp-Lys-Thr-Cys]-Nal-NH₂


[0058] Two grams of 3Å molecular sieve followed by NaCNBH₃ (36 mg) were added portion-wise in 15 minute increments to a solution of D-Phe-c[Cys Tyr (OBt)-D-Trp-Lys(BOC)-Thr(OBt) Cys] Nal-NH₂ (250 mg) and tris (acetoxymethyl)acetaldehyde. (120 mg) obtained by oxidation of triacetyl penta-erythritol with pyridinium dichromate or DMSO/oxalyl chloride/triethylamine) in methanol (10 ml) containing 10% acetic acid. The mixture was then stirred at room temperature for 30 minutes and heated for 4 hours. After filtration, the residue was partitioned between ethyl acetate and water. The ethyl acetate layer was washed with water, then aqueous NaHCO₃, and then dried (MgSO₄). The solvent was evaporated under reduced pressure to yield a residue (0.4 g) which was then dissolved in methanol (5 ml), treated with a NaOMe/MeOH solution (pH 10), stirred for 1 hour and finally neutralized with 1 N HCl to pH 5-6. After evaporation of solvent, the residue was dissolved in 90% aqueous TFA (5 ml) and stirred for 30 minutes. Volatiles were removed at reduced pressure and traces of TFA and water in the resulting residue were removed by co-evaporation with alcohol (2x). The residue was dried, then titrated with ether, and finally purified by HPLC using conditions similar to those described earlier, to yield 41 mg of (HO-CH₂)₃-C-CH₂-D-Phe-c[Cys-Tyr-D-Trp-Lys-Thr-Cys]-Nal-NH₂ as a colorless solid. MS (m/e) 1262.8.

Example 3.2 - Other Embodiments

[0059] The following somatostatin derivative, also referred to as BIM-23195, was synthesized in an analogous manner.

Example 4 - Synthesis of BIM-23197

[0060] The following somatostatin derivative, also referred to as BIM-23197, was synthesized in accordance with the invention.

Example 4.1 - 2-Bromoethanesulfonyl Chloride

[0061] Na 2-Bromoethanesulfonate (4.0 g) was treated with PCl₅ (11.8 g) while cooling in an ice bath. After reaching the liquid phase, the solution was heated at 90-120 °C for 1.5 hours in oil, cooled to room temperature, poured into 50 g of crushed ice, and then stirred for 15 min. The mixture was extracted with CH₂Cl₂ (3 x 30 ml) and combined extracts were washed with H₂O (2 x), 5% NaHCO₃ (2 x), and H₂O (2 x) again. Drying over anhydrous MgSO₄ and distillation under reduced pressure gave 2-bromoethanesulfonyl chloride as a colorless liquid (1.95 g, 42-44 °C/1 mm Hg).


Example 4.2 - Br-(CH₂)₂-SO₂-D-Phe-c[Cys-Tyr(tBu)-D-Trp-Lys(Boc)-Abu-Cys]-Thr(tBu)-NH(1-cyclopropyl-1-methyl)-ethyl

[0062] A solution of 2-bromoethane sulfonyl chloride (30 mg) in DMF (1 ml) was added dropwise to a solution of H-D-Phe-c[Cys-Tyr(tBu)-D-Trp-Lys(Boc)-Abu-Cys]-Thr(tBu)-(1-cyclopropyl-1-methyl)-ethyl (150 mg) and DIEA (55 mg) in DMF (2 ml) under N₂ at 0°C. The reaction mixture was stirred at 0-5 °C for 3 hours; solvent was then removed under reduced pressure. The residue was dissolved in ethyl acetate and washed with 5% citric acid (2 x), 5% NaHCO₃ (2 x) and brine (2 x). The solution was then dried over anhydrous MgSO₄, filtered, and condensed to dryness under reduced pressure. The product was further purified by a short silica gel column eluted with ethyl acetate. Fractions containing the product were pooled and the solvent was removed under reduced pressure, giving 105 mg of

Br-(CH₂)₂-SO₂-D-Phe-c[Cys-Tyr(tBu)-D-Trp-Lys(Boc)-Abu-Cys]-Thr(tBu)-NH(1-cyclopropyl-1-methyl)-ethyl as a slightly yellow solid. (Silica gel, CHCl₃/MeOH/HOAc (9:1:0.1), R_f=0.36).

Example 4.3 -


[0063]



[0064] A solution of Br-(CH₂)₂-SO₂-D-Phe-c[Cys-Tyr(tBu)-D-Trp-Lys(Boc)-Abu-Cys]-Thr(tBu)-NH(1-cyclopropyl-1-methyl)-ethyl (100 mg) and 2-hydroxyethylpiperazine (55 mg) in 2 ml of 1-propanol was refluxed under N₂ for 2.5 hours. The solution was then cooled to room temperature, and the solvent was removed under reduced pressure. The residue was then dissolved in ethyl acetate containing 5% MeOH and washed with brine (3 x). Finally, the solution was dried over anhydrous MgSO₄, filtered and condensed to dryness under reduced pressure, resulting in 110 mg of the above-identified solid. Without further purification, this compound was used directly in the next step.

Example 4.4 -


[0065]





[0066] 110 mg of the protected somatostatin derivative obtained in the previous step was dissolved in 10 ml of 90% TFA aqueous solution, and stirred at room temperature under N₂ for one hour. TFA and H₂O were removed under reduced pressure, and the residue was titrated with cold ether (3 x 10 ml). A slightly yellow solid was obtained; this material was further purified on preparative reverse phase HPLC, eluting with: 1) a NH₄OAc aqueous solution; and, 2) an HOAc aqueous solution. Lyophilization of the pooled fractions containing the above-identified product gave a white solid. (18 mg. ESI-MS, ((m+1)/e) 1252.7).

Example 4.5 - Other Embodiments


[0067] The following somatostatin derivatives were also synthesized in an analogous manner:



BIM-23190

**BIM-23191****BIM-23196****BIM-23202**Example 5 - Synthesis of Bombesin Derivatives

[0068] The following bombesin derivative, also referred to as BIM-26333, was synthesized in an analogous manner as described above:



[0069] Other peptide derivatives of the invention can be synthesized in an analogous manner, using synthetic modifications known in the art.

Results of Assays of Test PeptidesExample 6 - Binding Assays

[0070] In order to demonstrate the binding affinity of somatostatin (SRIF) analogs to the somatostatin receptor, the purified compounds described above were tested in somatostatin binding assays involving measurements of the *in vitro* inhibition of the binding of [¹²⁵I-Tyr¹¹]SRIF-14 to rat AR42J pancreas membranes. As indicated in Table I, purified somatostatin analogs of this invention demonstrated high binding affinities to these receptors. Additionally, the molecular weight, determined by mass spectrometry and estimated from the molecular structure, is listed in the table for each somatostatin derivative.

[0071] Similarly, the purified bombesin analog described above was tested in a bombesin binding assay. The binding

assay consisted of measurements of the *in vitro* inhibition of the binding of [¹²⁵I-Tyr¹¹] bombesin to rat AR42J pancreas membranes; from the assay, the binding affinity of the bombesin analog to the GRP receptor was determined to be about 21 nM.

5 Example 7 - Growth Hormone (GH) Inhibition Assay

[0072] Groups of five male Sprague Dawley rats (each having a weight between 250-300 g) were injected s.c. with a somatostatin derivative or saline. Thirty minutes prior to the selected post-drug time periods shown in table II (2 hours, 4 hours, 6 hours, 8 hours), rats were anesthetized with Nembutal i.p. (50 mg/kg). Fifteen minutes following anesthesia, an aliquot of blood was withdrawn by cardiac puncture over heparin to measure basal GH. Additionally, a
10 s.c. injection of D-Ala²-GRF (10 µg/kg) was given. Fifteen minutes later, blood was withdrawn to quantitate the stimulated GH, which was measured in plasma using a radioimmunoassay supplied by NIADK. The percentage of GH inhibition was calculated from differences obtained between basal and stimulated GH values.

[0073] Table II shows the effect of various purified somatostatin analogs as a function of time. The efficacy of D-Phe-c[Cys-Tyr-D-Trp-Lys-Thr-Cys]-Nal-NH₂ (BIM-23060) in inhibiting growth hormone in rats is compared with other somatostatin derivatives (BIM-23167, BIM-23179, and BIM-23181) of the invention. All derivatives demonstrate a surprising prolonged duration of action which decreases in a time-dependent fashion.

[0074] Additional experiments were conducted on D-Phe-c[Cys-Tyr-D-Trp-Lys-Abu-Cys]-Thr-NH₂, a somatostatin analog, and BIM-23190, BIM-23195 and BIM-23197, to determine the ED₅₀ (i.e., the concentration of each compound
20 required to inhibit fifty percent of growth hormone release after a specified time) of the respective compound. Experiments were conducted at a dose range of between 25 µg/kg and 0.25 µg/kg. Table III shows the surprising improvement of the somatostatin derivatives over the unmodified peptide at the various time intervals, indicating the time-dependent inhibition of stimulated GH release by the compounds of the invention.

25 Example 8 - Antiproliferative Assay

[0075] The purified somatostatin analogs described above were also tested for activity against rapidly proliferating cells. Table IV describes the effect of these peptides on the growth of AR42J rat pancreas tumor cells. Unlike natural somatostatin, the derivatives of the invention demonstrate substantial anti-proliferative activity. Referring now to Fig.
30 1, both BIM-23014C (a somatostatin analog) and BIM-23118 (a derivative of BIM-23014) inhibit the growth of AR42J rat pancreas tumor cells in a concentration-dependent fashion, with BIM-23118 being the more effective of the two compounds.

Both compounds inhibit tumor cell growth to a greater extent than unmodified somatostatin analogs at equivalent concentrations.

35 Example 9 - Thymidine Uptake Assay

[0076] In this assay, stock cultures of Swiss 3T3 cells are grown in Dulbecco's Modified Eagles Medium (DMEM) and supplemented with 10% fetal calf serum in a humidified atmosphere of 10% CO₂ and 90% air at 37°C. Cells were
40 then seeded into 24-well cluster trays and used four days after the last change of medium. In order to arrest cells in the G1/G0 phase of the cell cycle, the a serum-free DMEM was used 24 hours prior to the thymidine uptake assay; cells were then washed twice with 1 ml aliquots of DMEM (-serum, 0.5 µM) and [methyl-³H] thymidine (20Ci/mmol, New England Nuclear). Bombesin derivatives were initially tested at 0.001, 0.01, 0.1, 1, 10, 100, 100 nM. After 28 hours at 37°C, [methyl-³H] thymidine incorporation into acid-insoluble pools was assayed as follows. Cells were first
45 washed twice with ice-cold 0.9% NaCl (1 ml aliquots); acid-soluble radioactivity was then removed by 30-minute incubation at 40°C with 5% trichloroacetic acid (TCA). The cultures were then washed once (1 ml) with 95% ethanol and solubilized by a 30-minute incubation with 1 ml of 0.1N NaOH. The solubilized material was transferred to vials containing 10 ml ScintA (Packard), and the radioactivity determined by liquid scintillation spectrometry. This assay demonstrates the ability of the bombesin derivatives to stimulate thymidine uptake into the cells. The EC₅₀ was calculated
50 to be 0.48 nM, thus demonstrating that the bombesin derivatives of the invention are potent simulators of thymidine uptake.

Methods of Use

[0077] The peptide derivatives of the invention may be administered to a mammal, particularly a human, in one of the traditional modes (e.g., orally, parenterally, transdermally, or transmucosally), in a sustained-release formulation using a biodegradable, biocompatible polymer, or by on-site delivery (e.g., in the case of an anti-cancer bombesin or somatostatin derivatives, to the lungs) using micelles, gels and liposomes. Dosages are generally the same as those

currently used for therapeutic peptides in humans.

[0078] Additionally, the peptide derivatives of the invention are suitable for the improved treatment of diseases which are susceptible to treatment by the corresponding unmodified peptide. In particular, the somatostatin derivatives described above are suitable for the treatment of cancer, acromegaly, pancreatitis, trauma induced proliferation, diabetes, diabetic retinopathy, restenosis following angioplasty, AIDS, neurogenic inflammation, arteritis, and gastrointestinal problems including diarrhea.

TABLE I-

IN VITRO BINDING AFFINITIES AND MOLECULAR WEIGHTS OF SOMATOSTATIN PEPTIDE DERIVATIVES			
	MW _{TEST}	MW _{CALC}	IC ₅₀ nM
SRIF - 14	-	-	0.17
SRIF - 28	-	-	0.23
BIM - 23107	1340.4	1340.40	0.30
BIM - 23118	1313.5	1313.52	0.30
BIM - 23135	1426.2	1426.64	2.52
BIM - 23158	1299.6	1299.54	0.33
BIM - 23167	1347.6	1347.55	0.09
BIM - 23173	1235.5	1235.46	0.11
BIM - 23179	1305.9	1305.55	0.12
BIM - 23181	1435.0	1434.62	0.25
BIM - 23182	1193.8	1193.42	0.12
BIM - 23183	1323.0	1322.49	0.22
BIM - 23190	1202.8	1202.47	0.20
BIM - 23191	1314.9	1314.61	0.08
BIM - 23195	1150.8	1150.39	0.08
BIM - 23196	1243.7	1243.50	0.09
BIM - 23197	1252.7	1252.55	0.29
BIM - 23201	1262.8	1262.53	0.14
BIM - 23202	1247.0	1246.53	0.18

TABLE II-

INHIBITION OF STIMULATED GROWTH HORMONE RELEASE IN RATS BY SOMATOSTATIN PEPTIDE DERIVATIVES				
INHIBITION (PERCENTILE CONTROL) 25 µG/KG				
	2 Hours	4 Hours	6 Hours	8 Hours
BIM-23060	86.39	64.96	47.62	38.15
BIM-23167	92.67	79.54	59.72	50.14
BIM-23179	92.79	63.85	67.78	68.26
BIM-23181	99.24	77.07	60.56	56.12

TABLE III-

INHIBITION OF STIMULATED GROWTH HORMONE RELEASE IN RATS BY SOMATOSTATIN PEPTIDE DERIVATIVES ADMINISTERED S.C.				
ED 50 ($\mu\text{g/kg}$)				
	2 Hours	4 Hours	6 Hours	8 Hours
BIM-23023	0.48	1.11	2.26	4.32
BIM-23190	0.68	0.57	0.76	1.04
BIM-23195	1.19	3.13	2.08	3.23
BIM-23197	1.01	0.59	1.14	1.59

TABLE IV-


ANTIPROLIFERATIVE ACTIVITY OF SOMATOSTATIN PEPTIDE DERIVATIVES	
CELL GROWTH (PERCENT OF CONTROL) ¹	
SRIF - 14	91.3
SRIF - 28	98.0
BIM-23014C	74.1
BIM-23107	67.5
BIM-23109	72.1
BIM-23118	61.0
BIM-23135	62.9
BIM-23167	60.2
BIM-23173	67.9
BIM-23181	69.1
BIM-23182	68.7
BIM-23183	69.1
BIM-23195	69.2
BIM-23197	66.4

¹ Concentration 100 nM, AR42J Rat Pancreas Tumor Cells after 8 days.

Claims

1. A peptide derivative comprising:

a biologically active peptide moiety, and
at least one substituent attached to said peptide moiety, wherein said substituent is Compound I, wherein Compound I is:




wherein:

R_0 is O, S or NR_5 , wherein R_5 is H or (C_1-C_6) alkyl;
 each R_1 and R_2 , independently, is H, $(CH_2)_mOR_6$, or $CH(OR_7)CH_2OR_8$, wherein R_6 is H or (C_2-C_7) acyl, and
 each R_7 and R_8 , independently, is H, (C_2-C_7) acyl, or $C(R_9)(R_{10})$, wherein each R_9 and R_{10} , independently, is
 H or (C_1-C_6) alkyl;
 or each R_1 and R_2 is $=CHCH_2OR_{11}$, wherein in R_1 and R_2 independently, R_{11} is H or (C_2-C_7) acyl, and m is
 an integer between 1 and 5, inclusive; and
 one of R_3 or R_4 is $(CH_2)_nR_{12}$ or $(CH_2)_nCH(OH)R_{12}$, wherein R_{12} is CO, CH_2 , or SO_2 , and n is an integer
 between 1 and 5, inclusive;
 and the remaining R_3 or R_4 is H, (C_1-C_6) hydroxyalkyl, or (C_2-C_7) acyl;

wherein said peptide moiety is attached to each of said substituents by a $CO-N$, CH_2-N , or SO_2-N bond
 between said substituent and a nitrogen atom of the N-terminus or a side chain of said peptide moiety.

2. The peptide derivative of claim 1, wherein R_{12} is CH_2 or SO_2 .
3. The peptide derivative of claim 1 or claim 2,
 wherein said peptide moiety is selected from the group consisting of: somatostatin, bombesin, calcitonin, calcitonin
 gene related peptide (CGRP), amylin, parathyroid hormone (PTH), gastrin releasing peptide (GRP), melanocyte
 stimulating hormone (MSH), adrenocorticotrophic hormone (ACTH), parathyroid related peptide (PTHrP), luteiniz-
 ing hormone-releasing hormone (LHRH), growth hormone releasing factor (GHRF), growth hormone releasing
 peptide (GHRP), cholecystokinin (CCK), glucagon, Bradykinin, glucagon-like peptide (GLP), gastrin, enkephalin,
 neuromedins, endothelin, substance P, neuropeptide Y (NPY), peptide YY (PYY), vasoactive intestinal peptide
 (VIP), guanylin, pituitary adenylate cyclase activating polypeptide (PACAP), beta-cell tropin, adenomedulin, and
 derivatives, fragments, and analogs thereof.
4. The peptide derivative of claim 3, wherein said peptide moiety is somatostatin or a derivative, fragment or analog
 thereof.
5. The peptide derivative of claim 4, wherein said somatostatin analog is one of: H-D-Phe-c[Cys-Tyr-D-Trp-Lys-
 Abu-Cys]-Thr- NH_2 , H-D-Phe-c[Cys-Tyr-D-Trp-Lys-Thr-Cys]-Nal- NH_2 , and H-D-Nal-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-
 Thr- NH_2 .
6. The peptide derivative of claim 3, wherein said peptide moiety is bombesin or a derivative, fragment or analog
 thereof.
7. A dimeric peptide derivative, comprising:
 two biologically active peptide moieties, and
 at least one substituent attached to one of said peptide moieties, wherein said substituent is Compound IV,
 wherein Compound IV is:



wherein:

R_0 is O, S or NR_5 , wherein R_5 is H or (C_1-C_6) alkyl;

each R_1 and R_2 , independently, is H, $(CH_2)_mOR_6$, or $CH(OR_7)CH_2OR_8$, wherein R_6 is H or (C_2-C_7) acyl, and each R_7 and R_8 , independently, is H, (C_2-C_7) acyl, or $C(R_9)(R_{10})$, wherein each R_9 and R_{10} , independently, is H or (C_1-C_6) alkyl;

or each R_1 and R_2 is $=CHCH_2OR_{11}$, wherein R_{11} in R_1 and R_2 , independently, is H or (C_2-C_7) acyl, and m is an integer between 1 and 5, inclusive; and

each R_3 or R_4 , independently, is $(CH_2)_nR_{12}$ or $(CH_2)_nCH(OH)R_{12}$, wherein R_{12} is CO, CH_2 , or SO_2 , and n is an integer between 1 and 5, inclusive; and

wherein at least one of said peptide moieties is attached to each of said substituents by a CO-N, CH_2 -N, or SO_2 -N bond between said substituent and a nitrogen atom of the N-terminus or a side chain of one of said peptide moieties.

8. The use of a peptide derivative as claimed in any one of claims 1 to 7 for the manufacture of a medicament.

9. A pharmaceutical composition comprising a peptide derivative as claimed in any one of claims 1 to 7.

10. A peptide derivative as claimed in any one of claims 1 to 7 for use in therapy.

**Effect of Somatostatin Analogs on the
Proliferation of AR42J Rat Pancreatic
Tumor Cells**




Fig. 1



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 02 02 6863

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
D,Y	WO 88 02756 A (SANDOZ AG ;SANDOZ AG (CH); SANDOZ AG (DE)) 21 April 1988 (1988-04-21) * claims 1,27; example 4 *	1-10	C07K7/08 C07K14/655
D,Y	WO 89 09786 A (SANDOZ AG ;SANDOZ AG (CH)) 19 October 1989 (1989-10-19) * claim 1 *	1-10	
			TECHNICAL FIELDS SEARCHED (Int.Cl.7)
			C07K
The present search report has been drawn up for all claims			
Place of search MUNICH		Date of completion of the search 14 January 2003	Examiner Deffner, C-A
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document</p>			

EPO FORM 1503 03 02 (P04C01)

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 02 02 6863

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

14-01-2003

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 8802756 A	21-04-1988	AT 406680 B	25-07-2000
		AT 79491 A	15-12-1999
		AU 617986 B2	12-12-1991
		AU 7956487 A	14-04-1988
		AU 634664 B2	25-02-1993
		AU 8015091 A	31-10-1991
		BE 1003752 A4	09-06-1992
		BG 60272 B2	31-03-1994
		CH 682632 A5	29-10-1993
		CH 680512 A5	15-09-1992
		CZ 8805618 A3	14-08-1996
		DD 298932 A5	19-03-1992
		DK 532787 A	14-04-1988
		WO 8802756 A2	21-04-1988
		ES 2007418 A6	16-06-1989
		FI 874495 A	14-04-1988
		FI 950960 A ,B,	01-03-1995
		FR 2609991 A1	29-07-1988
		FR 2619566 A1	24-02-1989
		GB 2199829 A ,B	20-07-1988
		GB 2199831 A ,B	20-07-1988
		GB 2233652 A ,B	16-01-1991
		GR 871567 A1	16-02-1988
		HR 940990 A1	30-04-1997
		HU 46710 A2	28-11-1988
		HU 210192 B	28-02-1995
		IE 912442 A1	12-02-1992
		IE 65159 B1	04-10-1995
		IL 102184 A	30-05-1994
		IT 1221499 B	06-07-1990
		JP 2744910 B2	28-04-1998
		JP 3014599 A	23-01-1991
		JP 1921772 C	07-04-1995
		JP 6045639 B	15-06-1994
		JP 63101399 A	06-05-1988
		KR 9616861 B1	23-12-1996
		LU 87014 A1	03-05-1988
		NL 8702345 A ,B	02-05-1988
		NZ 222133 A	25-02-1993
		NZ 234094 A	25-02-1993
		NZ 234095 A	25-02-1993
		PL 268173 A1	01-09-1988
		PL 154068 B1	28-06-1991
		PT 85904 A ,B	01-11-1987
		RO 101204 A2	10-01-1992
		SE 8703938 A	14-04-1988

EPO FORM P4459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 02 02 6863

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

14-01-2003

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 8802756 A		SE 518630 C2	05-11-2002
WO 8909786 A	19-10-1989	AT 900689 A	15-01-1997
		AU 3263789 A	12-10-1989
		AU 3362889 A	03-11-1989
		BE 1004357 A4	10-11-1992
		CH 682152 A5	30-07-1993
		DE 3990350 T0	26-04-1990
		DK 163689 A	30-10-1989
		WO 8909786 A1	19-10-1989
		ES 2015645 A6	01-09-1990
		FR 2629825 A1	13-10-1989
		GB 2218102 A ,B	08-11-1989
		GB 2246782 A ,B	12-02-1992
		IE 930109 L	08-10-1989
		IL 89881 A	30-05-1994
		IT 1235894 B	23-11-1992
		JP 1305099 A	08-12-1989
		JP 7089994 A	04-04-1995
		LU 87495 A1	14-11-1989
		NL 8900864 A	01-11-1989
		NZ 228677 A	26-08-1994
		SE 8901241 A	02-02-1990
		US 5541159 A	30-07-1996
		ZA 8902570 A	28-12-1990
		FR 2682680 A1	23-04-1993

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☒ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.